Supplement
Curcumin
Curcumin, from turmeric, is one of the world's best-selling 'anti-inflammatory' supplements and one of the most studied — with a research literature complicated by poor bioavailability, small trials, and a molecule chemists flag as prone to producing false signals in laboratory assays. What survives that noise is narrower than the shelf suggests.
Quick verdict
Meta-analyses support reduced knee osteoarthritis pain versus placebo and lower C-reactive protein — both from small, heterogeneous trials using assorted formulations. No evidence connects curcumin to ageing outcomes, and 'inflammation' on a blood test is a marker, not a disease.
The assessment
Claim by claim
Each claim is graded on its own evidence. A grade for one claim says nothing about the others.
| Claim | What was measured | Evidence |
|---|---|---|
| Reduces knee osteoarthritis pain | Physical function | Early |
| Lowers C-reactive protein | Surrogate biomarker | Early |
| Extends human lifespan or slows ageing | Lifespan | Insufficient |
Reduces knee osteoarthritis pain
Early human evidenceOutcome measured: Physical function — A measured capability such as walking speed, grip strength or VO₂ max.
Meta-analysis of randomised trials finds curcumin better than placebo for knee osteoarthritis pain and function, in the range of — and in some comparisons similar to — NSAIDs, with fewer gastrointestinal complaints. The trials are small and use different formulations, which keeps the confidence modest.
Why this grade — the appraisal in full
One or a small number of small, short or preliminary human studies. Directionally interesting, not yet dependable.
- Strongest study design. Meta-analysis of RCTs.
- Human research volume. 1 human study, 0 participants in total.
- What was measured. 1 human study measured a clinical or functional outcome rather than a laboratory marker alone.
- Replication. The supporting result has not been independently replicated in humans.
Limitations. Small heterogeneous trials, multiple proprietary formulations, and strong publication-bias risk in this literature.
| Study | Design | Population | Finding |
|---|---|---|---|
| [1]Efficacy and safety of curcumin therapy for knee osteoarthritis: A Bayesian netw…Journal of ethnopharmacology · 2024 · PMID 38036015 | Meta-analysis of RCTsHuman | Size not recordedParticipants with a diagnosed condition | Supports the claimBayesian network meta-analysis: curcumin improved knee OA pain and function versus placebo. |
Lowers C-reactive protein
Early human evidenceOutcome measured: Surrogate biomarker — A laboratory marker measured as a stand-in for health. A change here does not by itself demonstrate a health benefit.
A meta-analysis of randomised trials using bioavailability-enhanced curcuminoid preparations found reduced circulating C-reactive protein. A marker moved is a marker moved: no outcome trial has tested whether curcumin's CRP effect translates into less disease.
Why this grade — the appraisal in full
One or a small number of small, short or preliminary human studies. Directionally interesting, not yet dependable.
- Strongest study design. Meta-analysis of RCTs.
- Human research volume. 1 human study, 0 participants in total.
- What was measured. Human studies measured surrogate biomarkers only. A change in a marker is not by itself a demonstrated health benefit.
- Replication. The supporting result has not been independently replicated in humans.
Limitations. Few trials, formulation-dependent, and CRP is a stand-in rather than a result.
| Study | Design | Population | Finding |
|---|---|---|---|
| [2]Are curcuminoids effective C-reactive protein-lowering agents in clinical practi…Phytotherapy research : PTR · 2014 · PMID 23922235 | Meta-analysis of RCTsHuman | Size not recordedMixed population | Supports the claimMeta-analysis: reduced CRP with bioavailability-enhanced curcuminoid formulations. |
Extends human lifespan or slows ageing
Insufficient evidenceOutcome measured: Lifespan — Death from any cause was measured.
No human or animal-replication evidence supports an ageing claim for curcumin.
Why this grade — the appraisal in full
Too little credible research exists to judge the claim either way.
- Available research. No usable studies are linked to this claim.
Limitations. Untested.
Human evidence
2 studies in people.
- [1]Meta-analysis of RCTs
- [2]Meta-analysis of RCTs
Animal and laboratory evidence
Shown separately, and never used to support a human claim.
No preclinical study is currently linked on this page.
Before anything else
Safety and interactions
Well tolerated in trials at common doses. High-dose or enhanced-absorption formulations have been associated with rare liver injury case reports, and curcumin can interact with anticoagulants.
The ledger
Grade history
22 August 2026
First published appraisal of this claim. Study links added: PMID 38036015.
22 August 2026
First published appraisal of this claim. Study links added: PMID 23922235.
22 August 2026
First published appraisal of this claim.
Falsifiability
What would change our view
Large trials of a standardised formulation with clinical endpoints; the field's small-trial, many-formulations pattern is exactly where publication bias lives.
Check everything
Sources
Every citation links to its PubMed record. Bibliographic details are retrieved from PubMed, not written by us.
- [1]Efficacy and safety of curcumin therapy for knee osteoarthritis: A Bayesian network meta-analysis Zhao J et al.. Journal of ethnopharmacology. 2024. PMID 38036015 · doi:10.1016/j.jep.2023.117493
- [2]Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis Sahebkar A. Phytotherapy research : PTR. 2014. PMID 23922235 · doi:10.1002/ptr.5045